GLAXOSMITHKLINE PLC Form 6-K April 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 April 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyteb) Position/status Company Secretary

Initial notification/
Initial notification

' amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type

3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)

each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 11

April 2019.

Price(s) Volume(s)

£15.7335 35

n/a (single transaction)

Aggregated information

Aggregated volume

c) Price(s) and volume(s)

Price

e) Date of the transaction 2019-04-11

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr I W Whyte

b) Position/status PCA of Mrs V A Whyte (Company Secretary)

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type

3. of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 11

April 2019.

Price(s) Volume(s)

£15.7335 880

n/a (single transaction)

Aggregated information

c) Price(s) and volume(s)

d) Aggregated volume

Price

e) Date of the transaction 2019-04-11

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs D Connor

b) Position/status

PCA of Mr R G Connor
(President, Global Vaccines)

c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type

3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)

each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary

Shares following the re-investment of dividends paid to shareholders on 11

April 2019.

c) Price(s) and volume(s)

Price(s) Volume(s) £15.7335 645 n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction

2019-04-11

Place of the transaction

London Stock Exchange

(XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 12, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc